Andrew A. Butler

Distribution of viable tumor cells in CANOPY-N surgery samples in A, all patients, B, the CD8-low subgroup, and C, the CD8-high subgroup.

Changes in T-cell phenotype distribution from screening to surgery for CANOPY-N as A, a T-cell phenotype count and B, a fraction of the total phenotypes per arm/time point.

A, PFS and B, OS by low T-cell–inflamed signature and C, PFS and D, OS by high T-cell–inflamed signature for CANOPY-1.

Baseline characteristics for CANOPY-1 and CANOPY-N population subsets

A, CD8 central tumor levels by PD-L1 subgroups and B, summary of patient characteristics at baseline by PD-L1 subgroup for CANOPY-1.

Changes in T-cell phenotype distribution from screening to surgery for CANOPY-N as A, a T-cell phenotype count and B, a fraction of the total phenotypes per arm/time point.

Cell phenotypes assessed by QIF: A, CD11b/CD66b stained for polymorphonuclear granulocytes (or neutrophils); B, CD163 stained for monocyte-lineage macrophages (or tumor-associated macrophages); and C, FOXP3/CD3 stained for regulatory T cells.

Comparison of CD8 subgroups (median cut-off) with T-cell phenotypes for CANOPY-1, by A, CD8 level and B, T-cell phenotype.

(A) Total CD8+ T cells, (B) intratumoral CD8+ T cells, (C) CD163+ TAMs, (D) CD66b+CD11b+ myeloid cells, (E) and FOXP3+ regulatory T cells by treatment arm in CANOPY-N. aCD163 is a marker for TAMs and was normalized by total detectable cells. bFOXP3 is a marker for regulatory T cells and was normalized by the abundance of CD3+ cells. CD66b expression is a marker for granulocytes including neutrophils, and CD11b is a marker for myeloid cells.

T-cell phenotypes derived from VisioPharm IA software algorithm were established under pathology review using panCK (purple) as the tumor marked-up area. Semi-automatic scoring of CD8 (brown) in panCK-negative tumor stroma and panCK-positive carcinoma cell compartments was performed, and representative T-cell phenotypes are depicted.